| Stage | IPGP | % of rev | NVDA | % of rev | Gap · A − B |
|---|---|---|---|---|---|
| Revenue | $288M | 100.00% | $96.2B | 100.00% | NVDA ×334.68 |
| Gross profit | $117M | 40.71% | $72.1B | 74.98% | NVDA +34.3pp |
| Operating income | $21M | 7.23% | $63.7B | 66.24% | NVDA +59.0pp |
| Pre-tax income | $28M | 9.88% | $71.5B | 74.32% | NVDA +64.4pp |
| Net income | $20M | 7.05% | $59.7B | 62.03% | NVDA +55.0pp |
| Stage | IPGP | NVDA | Gap · A − B |
|---|---|---|---|
| Revenue | $288M100.00% | $96.2B100.00% | NVDA ×334.68 |
| Gross profit | 40.71%$117M | 74.98%$72.1B | NVDA +34.3pp |
| Operating income | 7.23%$21M | 66.24%$63.7B | NVDA +59.0pp |
| Pre-tax income | 9.88%$28M | 74.32%$71.5B | NVDA +64.4pp |
| Net income |
| 7.05%$20M |
| 62.03%$59.7B |
| NVDA +55.0pp |
None
No disclosed counterparties: IPGP.